Adaptive Biotechnologies (ADPT) EBIAT (2018 - 2025)
Adaptive Biotechnologies (ADPT) has disclosed EBIAT for 8 consecutive years, with -$13.6 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 59.82% to -$13.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$59.5 million through Dec 2025, up 62.73% year-over-year, with the annual reading at -$59.5 million for FY2025, 62.72% up from the prior year.
- EBIAT hit -$13.6 million in Q4 2025 for Adaptive Biotechnologies, down from $9.5 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $9.5 million in Q3 2025 to a low of -$69.5 million in Q4 2023.
- Historically, EBIAT has averaged -$42.9 million across 5 years, with a median of -$46.9 million in 2024.
- Biggest five-year swings in EBIAT: plummeted 73.7% in 2023 and later surged 129.74% in 2025.
- Year by year, EBIAT stood at -$61.4 million in 2021, then surged by 34.9% to -$40.0 million in 2022, then tumbled by 73.7% to -$69.5 million in 2023, then skyrocketed by 51.35% to -$33.8 million in 2024, then surged by 59.82% to -$13.6 million in 2025.
- Business Quant data shows EBIAT for ADPT at -$13.6 million in Q4 2025, $9.5 million in Q3 2025, and -$25.6 million in Q2 2025.